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Abstract
Dendritic cells (DCs) are professional antigen-presenting cells that are specialized in the uptake of
antigens and their transport from peripheral tissues to the lymphoid organs. Over the last decades,
the properties of DCs have been intensely studied and much knowledge has been gained about the
role of DCs in various diseases and health conditions where the immune system is involved,
particularly in cancer and autoimmune disorders. Emerging clues in autoimmune diseases, suggest
that dendritic cell dysregulation might be involved in the development of various autoimmune
disorders in both adults and children. However, studies investigating a possible contribution of DCs
in autoimmune diseases in the pediatric population alone are scanty. The purpose of this review is
to give a general overview of the current literature on the relevance of dendritic cells in the most
common autoimmune conditions of childhood.
Background
Autoimmune disorders are chronic disabling disorders in
which underlying defects in the immune response result-
ing in an inappropriate response to self-tissues. Collec-
tively, autoimmune diseases are thought to affect
approximately 14–22 million people in the United States,
according to the American Autoimmune Related Diseases
Association (AARDA) representing greater than 80 unique
disorders [1], which affect preferentially women.
Autoimmune disorders in children are less common but
important to diagnosis, as immunomodulating therapy
can prevent considerable mobility and mortality, and
improve the survival of many of these patients. Autoim-
mune diseases are characterized by the loss of tolerance
against self-determinants, activation of autoreactive lym-
phocytes and/or autoantibodies, with pathological dam-
age that is organ specific or systemic.
A clear understanding of the mechanisms by which
autoimmune responses are triggered leading to the activa-
tion and/or induction of autoreactive lymphocytes and to
the breakdown of immunological self-tolerance are not
yet fully understood. Currently, multiple lines of evidence
indicate that DCs may also participate in the onset of
autoimmune diseases. [2-5]. Animal models show the
transfer of DCs isolated from donors with acute autoim-
mune disease or propagated in vitro under conditions that
induce maturation, generates a strong T helper (Th)-1
response, eventually culminating in autoimmune disease
[6]. For instance, one of the hallmarks of systemic autoim-
mune diseases, such as systemic lupus erythematosus
(SLE), is the immune response to nuclear autoantigens.
Several studies have proposed that DCs may acquire the
nuclear autoantigens from the apoptotic cells to initiate
the systemic autoimmune responses [7,8]. On the other
hand, experimental models of diabetes in mice suggest
that DCs may trigger autoimmunity by initiating a local or
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systemic response to an infective agent [9]. Increased
numbers of DCs have been described in chronic arthritis
synovial membrane and fluids [10-12]. However, there
have been a limited number of studies investigating the
role of DCs in the immunopathogenesis of autoimmune
disorders in childhood.
We think that, a better understanding of unique patho-
genic involvement of DCs in autoimmune diseases will
hopefully lead to the development of better, more tar-
geted and less toxic therapies and could contribute to
improve their outcome. Therefore, targeted modulation
of DC function may open new treatment options aiming
at alleviating DC-driven autoimmune responses. In this
review, an attempt has been made to summarize recent
data on DCs physiology in autoimmune diseases in the
pediatric population.
Dendritic cells: key cells in autoimmune diseases?
Briefly, DCs are a population of bone marrow-derived leu-
kocytes that efficiently link the innate and adaptive
immune systems and play a crucial part in initiating,
amplifying and controlling the immune response to path-
ogenic microorganisms [13]. DCs reside in and traffic
through non-lymphoid peripheral tissues where they
develop to a stage referred to as immature DCs, continu-
ously surveying the environment for invading microor-
ganisms. These immature DCs (iDCs) are characterized by
high capability for antigen capture and processing, but
low antigen presentation and T cell stimulatory capabili-
ties. DCs in the periphery are triggered by exposure to
microbial agents such as lypopolysaccharide (LPS) or
inflammatory mediators such as tumor necrosis factor
(TNF-α) and interleukin-1 (IL-1) are induced to enter in a
maturation process [14,15].
During their conversion from immature to mature cells,
DCs undergo a number of phenotypic and functional
changes. They lose their ability to capture antigen and
transform into efficient antigen presenting cells (APCs).
The process of DC maturation is characterized by an
increased surface expression of major histocompatibility
complex (MHC) class I and class II, up-regulation of T-cell
costimulatory molecules such as CD80, CD86 and CD40,
secretion of chemokines and cytokines, surface expression
of adhesion molecules and chemokines receptors [16].
Chemokine receptors promote DC migration out of non-
lymphoid tissues into the blood or afferent lymphoid ves-
sels, as well as enhanced T cells stimulation. These
migratory cells reach secondary lymphoid organs where
they home to the T cell areas, and interact with, stimulate
and direct primary T- and B- lymphocytes responses. Mat-
uration of DCs modifies expression of chemokines recep-
tors and adhesion molecules, causing migration from the
periphery to the T cell zone of secondary organs. [17,18]
The types of T cell-mediated immune responses induced
can vary depending on the specific DC lineage (myeloid
vs. lymphoid) and maturation stage in addition to the
activation signals received from the surrounding microen-
vironment. During the primary immune responses, the
DC subset is a critical determinant for polarizing naive T
cells into Th1 or Th2 cells [19]. Studies over the last dec-
ade have demonstrated that the distinct subsets of human
DCs (myeloid and plasmacytoid DCs a form of lymphoid
DC) induce the different profiles of T cells responses
[13,15,20]. For example, studies have shown that myeloid
DCs (mDCs) produce a large amount of IL-12 and prefer-
entially induce Th1 development, whereas plasmacytoid
DC (pDCs) secrete lower amounts of IL-12 and primarily
elicit Th2 development [21-24]. On the other hand, other
studies have suggested that functional differences between
DCs in guiding T cell responses might depend on not only
their lineage but also the microenvironment of cytokines
and/or inflammatory mediators in the primary immune
response [22,24].
Role of dendritic cells in children autoimmune diseases
Dendritic cells in children lupus
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by polyclonal B-cell activation, the
production of antinuclear antibodies (ANAs) and sys-
temic inflammatory injury of multiple organs. SLE consti-
tutes up to 10 percent of the new diagnosis of systemic
rheumatic diseases in childhood [25]. The pathogenesis of
SLE is correlated with both genetic predisposition and
environmental influences. The contribution of these two
factors may differ between individuals, but the resulting
malfunctions in the immune system and the production
of autoantibodies plays a pivotal role in the pathogenesis
of SLE; however, the mechanisms of how this occurs in
SLE pathogenesis remains unclear. Lupus has been con-
sidered mainly as B-cell disease resulting from altered T-
cell and B-cell interactions [26,27]. The immune system
abnormalities seen in patients with lupus are diverse and
include CD4+ autoreactive T cells that are specific for
ubiquitous self-peptides and provide pathogenic B cell
help, ANA-producing autoreactive B cells, alterations in
Th1 and/or Th2 lymphocyte functions resulting in pro-
duction of cytokines that up-regulate autoantibody pro-
duction by B cell, promote immune complex formation
which determine different subsets of the disease
[26,28,29].
The mechanisms by which an autoimmune response is
triggered and activation of autoreactive lymphocytes is
initiated and maintained in SLE are not fully understood.
Different groups have proposed that T cell abnormalities
in SLE could be induced or promoted, at least in part, by
alterations in DCs phenotype and function, because these
are key regulators of the immune system [30-32]. Naïve TPediatric Rheumatology 2007, 5:16 http://www.ped-rheum.com/content/5/1/16
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lymphocytes circulate through the blood and secondary
lymph organs (SLOs), where they scan for antigen-histo-
compatibility complex molecule displayed on dendritic
cells. If accompanied by appropriate co-signals, naïve T
cell-DC interaction induces T cell clonal expansion and
promotes migration either to B cell area to assist in anti-
body production or out of the lymphoid tissue to sites of
inflammation [33]. Moreover, DCs appear to be the only
class of antigen presenting cells that have the capacity to
stimulate the expansion of naïve T cells and thereby initi-
ate primary immune responses [15,34,35]. DCs can also
generate regulatory T cells that suppress activated T cells, a
function of probable importance in autoimmunity [36].
Type I interferons (IFNs) are produced in response to viral
and non-viral infections and may be induced during T
cell-DC interactions in the absence of infecting agents
[37]. Type I IFNs have been shown to act as a maturation
factor for DCs and to increase DC maturation [38,39].
Patients with SLE have increased blood levels of IFN-α,
which correlate to disease activity [32,40-42]. In addition,
drug-induced lupus has been reported in hepatitis C or
cancer patients treated with recombinant IFN-α [43]. This
evidence suggests a significant role to the pDCs, the major
source of IFN-α in the blood, in the immunopathogenesis
of SLE. Palucka et al. [44] have been the first group to
identify how the interaction between lymphoid and mye-
loid DCs might play an important role initiating the
immune response in SLE patients. They linked a hyperac-
tivated secretion of IFN-α by DCs to the immunological
dysfunction observed in children with SLE. In brief, serum
from children with SLE induced monocytes to differenti-
ate into DCs. Furthermore, they found that DCs are stim-
ulated to proliferate when peripheral mononuclear cells
(PBMCs) from normal donors were cultured with the
serum of pediatric lupus patients. IFN-α was identified as
the cytokine responsible for this effect and, as seen in
other reports, pDCs were the major source of interferon in
the blood of these patients. From these findings, they have
formulated a hypothesis that explains the activation and
pivotal action of the type I IFN system in the development
of SLE. It is based on the activation of immature myeloid
dendritic cells through type I IFNα/β. IFN-matured mDCs
are proposed to efficiently capture autoantigens (apop-
totic cells and nuclesomes) and then present the antigens
to CD4+ T cells which initiate the expansion of autoreac-
tive T cells. The mDCs together with pDCs could help to
expand autoreactive B cells, followed subsequently by
autoantibody production. This abnormal immune reac-
tion could finally lead the immune system of lupus
patients to attack their own tissues with the subsequent
injury to various organ systems, including skin, kidney
and central nervous system [44-46]. Ronnblom et al.
implicated pDCs and IFN-α in adults with SLE [42,47].
Interesting others investigators have demonstrated in SLE
subjects that circulating immune complexes ((ICs), in
addition to INF-α, activates DCs and can induce cytokines
and chemokines implicated in SLE pathogenesis. For
instance, the local production of the chemokines IL-8,
MCP-1, and RANTES has been noted in inflamed joints of
SLE patients, and serum levels of MCP-1 and IP-10 are
higher in SLE patients than in controls [48,49]. Means et
al. demonstrated that anti-DNA autoantibody ICs were
able to activate DCs through a cooperative interaction
between Toll-like receptor 9 (TLR9) and FcγRIIa (CD32)
[50].
These findings may provide a framework for developing
better lupus therapies that the currently available, how-
ever more research is needed to clarify the exact role of
DCs in lupus pathogenesis.
DCs in Juvenile Dermatomyositis
Juvenile DM is the most common of the idiopathic
inflammatory myopathies in children. It is considered an
autoimmune disease of etiology and pathogenesis rela-
tively unknown. The inflammatory lesions consist of
perivascular, perifasicular and intradermal lymphocytes
infiltrates. The perivascular infiltrates are composed
mainly of CD4+ T lymphocytes, B lymphocytes, macro-
phages [51]. While the exact triggers of the immune
response in children with juvenile DM have not been
identified, recent studies have attempted to elucidate the
targets of such abnormal immune responses. The presence
of T cells indicates an ongoing immune response requir-
ing the presence of APCs. Emerging data suggest that DCs,
the most potent APCs, may be involved in the immun-
opathogenesis of the idiopathic inflammatory myopa-
thies (IIM). Mature DCs have been detected in
dermatomyositis and polymyositis muscle tissue, pre-
dominantly located in perivascular infiltrates and sur-
rounded muscle fibers [52]. Recently, our laboratory
demonstrated that pDCs populate muscle lesions of
patients with new-onset Juvenile DM [53]. We compared
samples of muscle tissue from children with Juvenile DM
to patients with non-inflammatory muscle disorders
using triple immunofluorescence analysis (Figure 1). We
found that pDCs populate muscle lesions of patients with
new onset JDM, the majorities of these pDCs were mature
as indicated by high CD83 expression and they were local-
ized in close proximity to T cells and B cells in the perimy-
sium and perivascular areas (Figure 2). Since such cellular
infiltrates contained a large proportion of T cells, presence
of mature pDCs is consistent with the idea that these infil-
trates are foci of inflammation. Furthermore, we also
found that DC-derived chemokines CCL21, CCL19 and
CXCL12 ("lymphoid" chemokines), which have been
demonstrated to be up regulated in ectopic secondary
lymphoid organs at sites of chronic inflammation [54-
56], were over-expressed within organized infiltrates inPediatric Rheumatology 2007, 5:16 http://www.ped-rheum.com/content/5/1/16
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Juvenile DM muscle lesions. The simultaneous presence
of DCs, T-and B-cells and the chemokine profile found in
the inflamed muscle tissue of these patients suggests that
interactions among these cells types might be instrumen-
tal in the local induction and maintenance of neo-lym-
phoid genesis in JDM muscle.
Recent advances in the study of patterns of gene expres-
sion with the use of microarray technology, has provide
new insights into the study of role of pDCs in the immu-
nopathogenesis of adult and Juvenile DM. A gene expres-
sion profile identified by microarray analysis and
consistent with IFN-mediated gene transcription in
inflammatory myositis was first reported by Tezak and
colleagues in a study of muscle biopsies from JDM and
age-matched controls [57]. They compared the gene
expression profile data from children with untreated Juve-
nile DM, positive for the DQA1*0501 allele, with data
from children with Duchene muscular dystrophy and
healthy pediatric controls, as well as profiles reflective of
intracellular antiviral response by using Affymetrix HuFL
Gene Chips. They found profound dysregulation in mus-
cle biopsies from children with Juvenile DM, most of the
dysregulated genes being interferon-inducible genes. This
pattern of gene expression found was consistent with an
of IFN α/β transcription cascade seen in an in vitro viral
resistance model. These findings gave additional support
to the hypothesis that the pathogenesis of Juvenile DM is
a response to an infection agent, particularly since tran-
scription of IFN-inducible genes is a hallmark of the host
defense mechanism against infection. From this profiling
data, the authors hypothesized a model of disease patho-
genesis that involves a repetitive cycle of muscle injury in
which both INF-α/β and INF-γ cascades lead to muscle
ischemia and increased production of TNF-α and nitric
oxide, which in turn, interact with the immune response
cascades in the endothelium and with infiltrating T and
pDCs, thus exacerbating the IFN-induced processes. In a
recent work from our laboratory [58], we investigated pat-
terns of gene expression profiling of peripheral blood cells
from adult and Juvenile DM and healthy controls by using
as well microarray analysis. We studied the expression lev-
els of 314 IFN-inducible genes between adult and Juvenile
DM and healthy controls. We found that in the most of
DM patients 93 out of 314 genes examined were overex-
pressed in DM patients, which correlated with disease
activity. The particular interest, we noted the increased
expression of a number of genes involved in muscle func-
tion, mitochondrial/oxidative phosphorylation and
immune function. Many genes previously demonstrated
by other investigators as overexpressed in other autoim-
mune diseases such as SLE [59,60], Sjögren's syndrome
[61] and inflammatory myopathies [62] were similarly
increased in our data. Together, our findings suggested
that pDCs are an important source of IFN-α/β in adult
and childhood DM and may therefore be of pathogenic
importance, and even more relevant the IFN-profile found
could points towards the type I IFN-α/β pathway as a can-
didate pathway for DM susceptibility genes.
DCs in Juvenile Inflammatory Arthritis
Juvenile arthritis is a group of chronic inflammatory dis-
eases in children collectively known as Juvenile Idiopathic
Architecture and cellular composition of inflammatory infil- trates in JDM muscle Figure 2
Architecture and cellular composition of inflamma-
tory infiltrates in JDM muscle. pDCs (arrow heads 
denote pDC aggregates) were localized in close proximity to 
B-cells (arrows denote CD20+ B cells) and T-cells (not 
shown). Magnification: × 40
Activated pDCs in JDM muscle Figure 1
Activated pDCs in JDM muscle. JDM muscle samples 
were stained for CD123 (green fluorescent avidin), CD83 
(Texas Red), and the nucleus (DAPI). Most of the pDCs in 
the JDM muscle were activated (CD123+ CD83+, yellow in 
overlay). Magnification: × 40.Pediatric Rheumatology 2007, 5:16 http://www.ped-rheum.com/content/5/1/16
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Arthritis (JIA). It is the most common chronic autoim-
mune arthropathies of childhood and an important cause
of disability. JIA is characterized by a persistent inflamma-
tory infiltrate within the synovial layer of the joints. The
findings of T cells and chronic synovial inflammation
have indicated a possible cellular-mediated immune
response. However, the presences of immune complexes,
complement, and inflammation in JIA have indicated a
possible B cells hyperreactivity [63]. T cells within the
hypertrophied synovium are activated, oligoclonal, and
has a bias towards a T helper (Th1) phenotype in oligoar-
ticular and polyarticular JIA. The immune response iden-
tified by the induction of Th1/Th2 cells may play an
important role in the immunopathogenesis of JIA [64,65].
However, it is unclear what causes clonal inflammatory
lymphocytes within the joints of these patients. One
mechanism could be through signals received from APCs
such as DCs. DCs may contribute to the synovitis by hom-
ing T cells as well as by the induction of cytokines belong-
ing to both Th1/Th2 cells. Varsani et al [66] have recently
found an increased number of cells with DC morphology,
in the joint of children with JIA. Specifically, they exam-
ined the expression of the receptor activator of NF-κB
(RANK), a TNF receptor-like surface protein derived from
DCs, and its ligand (RANKL). The RANK/RANKL pathway
is critical in bone erosion in conditions such as rheuma-
toid arthritis [67] and is involved in DC-T cell interac-
tions. They investigated the expression of RANK/RANKL
in paired samples of peripheral blood (PB) and synovial
fluid (SF) from JIA patients, as well as in monocyte-
derived dendritic cells by the reverse transcriptase-
polymerase chain reaction and flow cytometry. They
determined that RANK and RANKL were overexpressed in
cells from both PB and SF compartments of children with
JIA as compared to controls. Interesting, a large number of
RANK+ synovial cells had the phenotype of mature mye-
loid dendritic cells. Mature DC may play a central role in
the presentation of antigens to T cells and the production
of inflammatory cytokines. These RANK+ cells also
expressed the DC-specific adhesion receptor DC-SIGN
(CD209), which supports rolling of DC-SIGN+ cells on
the vascular ligand ICAM-2 under shear flow, a prerequi-
site for DC emigration from the blood into the peripheral
tissues. Another novel finding of this study was that the
majority of RANK+ DC-SIGN+ cells also expressed high
levels of the costimulatory molecule CD86; the binding of
this protein with CD28 antigen at the cell surface of T cells
could be a costimulatory signal for activation of the T-cell
in JIA synovium. Taken together, these findings suggest
that RANK+ DCs in children with JIA might contribute to
persistence and expansion of particular T cell subset
within inflamed joint of JIA patients.
Similarly, Palucka et al. [68] implicated INF-α production
by pDCs in the immunopathogenesis of JIA. They have
proposed that the induction of autoimmunity to nuclear
antigens during anti-TFN-α therapy appears to be induced
by IFN-α. They found that children with systemic onset
JIA (SoJIA) who did received anti-TNF therapy displayed
over-expression levels of IFN-α-regulated genes in their
blood leukocytes compared with patients without anti-
TNF therapy. In addition, they found that the IFN-α pro-
duction by pDCs generated from CD34+ hematopoietic
progenitors exposed to influenza virus was inhibited by
TNF. These findings led them to propose that the neutral-
ization of endogenous INF during anti-TNF therapy might
further switch the TNF/INF-α balance to a sustained IFN-
α secretion by pDCs with a well-known pathogenic effect,
and therefore a possible explanation to the lupus-like
symptoms develop during TNF blockade.
Role of dendritic cells in vasculities
Recent studies have investigated the participation of DCs
in the pathogenesis of various vascular inflammatory dis-
eases such as Giant Cell Arteritis (GCA) [69], Takayasu's
Arteritis [70] and atherosclerosis, which is now emerging
as an inflammatory syndrome [71]. Weyand et al [69,72]
have intensely investigated the mechanisms involved in
the persistence and expansion of DCs in the vessel wall of
medium-sized arteries from patients affected by GCA, the
most common form of systemic vasculities in human.
They found a number increased of mature (activated) DCs
positioned in the adventitia-media border of these vessels
(adventitial DCs), which were equipped molecularly to
contribute to vascular lesion. Moreover, these DCs might
be influenced by antigen-specific signaling from T cells,
which may extend and amplify DC antigen capabilities,
especially for the stimulation of cytotoxic responses.
The involvement of DCs in the immunopathogenesis of
Kawasaki disease, a multisystem vasculities associated
with cardiac complications in children, has been sug-
gested by Yilmaz and Colleagues [73]. They studied the
participation of DCs in the immunological abnormalities
seen in the coronary lesions of Kawasaki's patients. They
found an increased number of mature myeloid DCs
(S100+, Fascin+, HLA-DR+, CD83+) in the adventitia of
coronary arteries. Interesting, they observed mature DCs
with high HLA-DR expression in close proximity to T cells
evoking DC-T cell immunological synapse formation,
which suggested that mature arterial myeloid DCs might
be activating T cells in situ and may be a significant factor
in the pathogenesis of coronary arteritis in KD.
Aberrant DC function has also been implicated in other,
less prevalent autoimmune diseases in childhood such as
cutaneous scleroderma [74]. In addition, the pathogenic
role of DCs in the pathogenesis of Type I Diabetes has
been recently suggested in several studies [75,76]; how-Pediatric Rheumatology 2007, 5:16 http://www.ped-rheum.com/content/5/1/16
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ever the analysis of impact of DC malfunction in this dis-
ease has not been considered in this review.
Conclusion
Based on the evidence obtained from various autoim-
mune diseases described here, it is highly suggestive that
local or recruited DCs play a fundamental role in both
induction and maintenance of these disorders. Moreover,
direct analysis of DC phenotypes and DC-T cell interac-
tions is several autoimmune diseases bring light on the
pathogenesis of these autoimmune disorders. We must
take into account the delicate balance between immunity
and autoimmunity and the pivotal role DCs play in this
equilibrium. Future therapeutic regimes used to fight
autoimmune disease need to consider therapeutic options
based on specific modulation of pathogenic DCs that
induce and sustain autoimmune inflammation, which
could be curative or be able to induce long term remis-
sions.
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